Egetis Therapeutics AB (OSTO:EGTX) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EGTX Egetis Therapeutics AB OSTO:EGTX
66 GF Score
Price kr6.37
GF Value kr5.59
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Egetis Therapeutics AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

OSTO:EGTX vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Margin of Safety % (DCF Dividends Based) falls into.


OSTO:EGTX
66GF Score
Egetis Therapeutics AB OSTO:EGTX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (OSTO:EGTX) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.37 is trading 14% above its estimated GF Value™ of kr5.59. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for OSTO:EGTX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: kr5.59 vs. price of kr6.37 (14% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the OSTO:EGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USA0ABW:UKP0F:Germany
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
66GF Score

Get the complete analysis for OSTO:EGTX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.37
Price
kr5.59
GF Value